NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its clinical stage MALT1 inhibitor, was designated as a Fast Track product by the U.S. Food and Drug ...
In May 2025, the Treasury Department, as chair of the Committee on Foreign Investment in the United States (CFIUS), announced a new “fast track process to facilitate greater investment in U.S.
AVZO-103 targets Nectin4 and TROP2, aiming to deliver anticancer effects precisely to tumor cells, potentially reducing side effects. Fast track designation by the FDA expedites drug development and ...
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE: MRK) drugs with potential blockbuster sales. Merck's cholesterol treatment ...
Alnodesertib, combined with irinotecan, targets ATM-negative metastatic colorectal cancer, showing promise in the STELLA study with favorable safety and clinical activity. The FDA's fast track ...
Demonstrates the potential of SGR-1505 as a novel approach for diseases with high unmet medical need NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced that SGR-1505, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback